VIGL - Vigil Neuroscience, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 2.71

Open

$ 2.58

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.53 - $ 2.71

52 Week Range

$ 2.50 - $ 11.11

Volume

46,561

Average Volume

Market Cap

104.91M

Beta (5Y Monthly)

$ 0.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-26-2024	12-31-2023	10-K
2	11-07-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-10-2023	03-31-2023	10-Q
5	03-21-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-08-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-25-2022	12-31-2021	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JMP Securities Reiterates Market Outperfor...
04/19/2024 16:35:43

JMP Securities analyst Jason Butler reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Market Outperform and maintains $23 p...

JMP Securities Reiterates Market Outperfor...
04/18/2024 17:39:08

JMP Securities analyst Jason Butler reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Market Outperform and maintains $23 p...

Vigil Presents Key Findings From ILLUMINAT...
04/17/2024 20:21:18

- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathop...

HC Wainwright & Co. Maintains Buy on Vigil...
03/27/2024 13:32:05

HC Wainwright & Co. analyst Andrew Fein maintains Vigil Neuroscience (NASDAQ:VIGL) with a Buy and maintains $24 price ta...

Vigil Neuroscience: Q4 Earnings Insights
03/26/2024 13:20:05

Vigil Neuroscience Q4 EPS $(0.57) Misses $...
03/26/2024 11:28:39

Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of ...

Vigil Announces Oral Presentation On Small...
03/06/2024 21:41:53

Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...

Vigil Presents Poster On Impacts Of Misdia...
02/29/2024 21:35:55

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testingWAT...

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
01/08/2024 21:31:09

Vigil Neuroscience Says On Track To Report...
01/03/2024 21:36:54

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinica...

Morgan Stanley Downgrades Vigil Neuroscien...
12/19/2023 14:31:35

Morgan Stanley analyst Jeffrey Hung downgrades Vigil Neuroscience (NASDAQ:VIGL) from Equal-Weight to Underweight and lowers ...

why-is-rare-neurological-disease-focused-vigil-neuroscience-stock-trading-lower-today

Why Is Rare Neurological Disease Focused V...
11/17/2023 19:12:05

Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-...

Why Dolby Laboratories Shares Are Trading ...
11/17/2023 18:01:38

Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.

12-health-care-stocks-moving-in-fridays-intraday-session

12 Health Care Stocks Moving In Friday's I...
11/17/2023 17:31:21

us-stocks-edge-lower-housing-starts-rise-in-october

US Stocks Edge Lower; Housing Starts Rise ...
11/17/2023 14:51:24

U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the ma...

Wedbush Reiterates Outperform on Vigil Neu...
11/17/2023 14:07:41

Wedbush analyst Laura Chico reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Outperform and maintains $23 price target.

Vigil Neuroscience Reports Interim Data Fr...
11/16/2023 21:09:11

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target enga...

Wedbush Reiterates Outperform on Vigil Neu...
11/08/2023 13:59:19

Wedbush analyst Laura Chico reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Outperform and maintains $23 price target.

Vigil Neuroscience Q3 EPS $(0.53) Beats $(...
11/07/2023 12:28:44

Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(...

vigil-neurosciences-focus-on-neurodegenerative-diseases-analyst-says-pipeline-offers-upside-opportunities-to-valuation

Vigil Neuroscience's Focus On Neurodegener...
10/18/2023 18:26:28

JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenera...